Dermatology medications with the highest cost burden on Medicare Part D: Potential implications of the Inflation Reduction Act.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 38663745.
- Also identified by DOI 10.1016/j.jaad.2024.04.030.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Signed into law in August 2022, the Inflation Reduction Act includes provisions requiring the federal government to negotiate prices for medications covered under Medicare Part D. Initial negotiations will target drugs with the highest total spending and price increases relative to inflation. In this study, we identify dermatology prescriptions with the highest cost burden on Medicare Part D and analyze recent trends in total spending and unit costs.
Medical subject headings
- Medicare Part D
- Drug Costs
- Dermatologic Agents